PM: Philip Morris Confirms 2025 EPS Guidance

Philip Morris' decision to reaffirm 2025 EPS guidance signals management confidence in near‑term results despite industry headwinds. The company is highlighting execution of its smoke‑free transition as a core driver of guidance, pointing to continued volume growth in HTU (+11.0% YoY) and strong expansion in oral SFPs (+18.5% YoY). For investors, the guidance confirmation should be read in the context of steady topline scale ($40,648M in 2025 revenues) and sizeable net earnings ($11,848M). However, the company carries material leverage (long‑term debt of $45,134M) and a reported stockholders’ deficit of $(8,028)M on the balance sheet, which remain key considerations when assessing risk versus growth upside from smoke‑free products.

Smoke‑free products represented 22.8% of total 2025 shipment volume (179.1 billion of 786.5 billion equivalent units), underscoring the company’s pivot from combustible tobacco. HTU (IQOS) accounted for 19.7% of volume and grew 11.0% year‑over‑year, while oral SFPs rose 18.5% and e‑vapor doubled (0.4% share, +100% YoY). Despite strong SFP momentum, cigarettes remain the majority of shipments at 77.2% (607.4 billion units, -1.5% YoY). The mixed profile—declining but still dominant cigarette volumes alongside faster growth in smoke‑free categories—drives the dual narrative behind the reaffirmed EPS: near‑term earnings stability from the existing combustible franchise, and medium‑term growth potential from SFP scale.

Management’s near‑term messaging ties the EPS outlook to execution in the smoke‑free transformation and operational actions such as manufacturing optimization. The company also plans an organizational update (effective Jan 1, 2026) to two reporting units (International/U.S.) intended to improve agility and focus on SFP scale. Risks that could affect the trajectory behind the guidance include active litigation (for example, U.S. nicotine addiction suits related to ZYN and various international claims), regulatory uncertainty (FDA MRTP processes for IQOS, EU TPD notifications, potential novel‑product restrictions), and macro impacts such as currency volatility and inflation. Specific 2025 items of note include a $2.3B impairment tied to a Canada settlement exposure and a EUR 151M tax assessment in Germany related to product classification. These legal and regulatory factors, together with the company’s substantial debt load, contribute to the risk profile behind maintained EPS targets.